Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 5 (December)

1. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
   J Natl Cancer Inst, 96(23): 1762-9. [Abstract] [Full-text]
2. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
   J Natl Cancer Inst, 96(23): 1751-61. [Abstract] [Full-text]
3. Cis-retinol dehydrogenase: 9-cis-retinol metabolism and its effect on proliferation of human MCF7 breast cancer cells.
   Exp Cell Res, 303(1): 183-96. [Abstract] [Full-text]
4. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
   Eur J Cancer, 40(18): 2742-7. [Abstract] [Full-text]
5. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.
   Eur J Cancer, 40(18): 2726-33. [Abstract] [Full-text]
6. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer.
   Eur J Cancer, 40(18): 2717-25. [Abstract] [Full-text]
7. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
   Eur J Cancer, 40(18): 2667-75. [Abstract] [Full-text]
8. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
   Cancer Genet Cytogenet, 155(2): 108-18. [Abstract] [Full-text]
9. Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.
   Carcinogenesis, 25(12): 2293-301. [Abstract] [Full-text]
10. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.
    Carcinogenesis, 25(12): 2417-24. [Abstract] [Full-text]
11. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer.
    Carcinogenesis, 25(12): 2473-8. [Abstract] [Full-text]
12. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.
    Cancer Res, 64(23): 8694-701. [Abstract] [Full-text]
13. Membrane-associated and secreted genes in breast cancer.
    Cancer Res, 64(23): 8682-7. [Abstract] [Full-text]
14. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells.
    Cancer Res, 64(23): 8674-81. [Abstract] [Full-text]
15. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
    Cancer Res, 64(23): 8558-65. [Abstract] [Full-text]
16. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.
    Cancer Res, 64(23): 8541-9. [Abstract] [Full-text]
17. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Cancer Res, 64(23): 8534-40. [Abstract] [Full-text]
18. Quality-of-life concerns of African American breast cancer survivors within rural North Carolina: blending the techniques of photovoice and grounded theory.
    Qual Health Res, 15(1): 99-115. [Abstract] [Full-text]
19. Metastatic myoepithelioma of the breast.
    ANZ J Surg, 74(12): 1135-7. [Abstract] [Full-text]
20. Prospective trial of intraoperative radiation treatment for breast cancer.
    ANZ J Surg, 74(12): 1043-8. [Abstract] [Full-text]
21. Life course breast cancer risk factors and adult breast density (United Kingdom).
    Cancer Causes Control, 15(9): 947-55. [Abstract] [Full-text]
22. Geographic clustering of residence in early life and subsequent risk of breast cancer (United States).
    Cancer Causes Control, 15(9): 921-9. [Abstract] [Full-text]
23. Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors.
    Ann Surg Oncol, 11(12): 1045-55. [Abstract] [Full-text]
24. Associations between relationship support and psychological reactions of participants and partners to BRCA1 and BRCA2 testing in a clinic-based sample.
    Ann Behav Med, 28(3): 211-25. [Abstract] [Full-text]
25. Multi-channel 3-D cell culture device integrated on a silicon chip for anticancer drug sensitivity test.
    Biomaterials, 26(14): 2165-72. [Abstract] [Full-text]
26. Sentinel lymph node metastases detected by immunohistochemistry only do not mandate complete axillary lymph node dissection in breast cancer.
    Ann Surg Oncol, 11(12): 1056-60. [Abstract] [Full-text]
27. Randomized clinical trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of occult breast lesions.
    Br J Surg, 91(12): 1575-7. [Abstract] [Full-text]
28. Accuracy of typing and grading invasive mammary carcinomas on core needle biopsy compared with the excisional specimen.
    Virchows Arch, 445(6): 597-602. [Abstract] [Full-text]
29. Serum levels of soluble E-selectin in women with breast cancer.
    Br J Surg, 91(12): 1578-81. [Abstract] [Full-text]
30. Assessment of the current Medicare reimbursement system for breast cancer operations.
    Ann Surg Oncol, 11(12): 1037-44. [Abstract] [Full-text]
31. Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women.
    Am J Epidemiol, 160(12): 1177-83. [Abstract] [Full-text]
32. Standardization for image characteristics in telemammography using genetic and nonlinear algorithms.
    Comput Biol Med, 35(3): 183-96. [Abstract] [Full-text]
33. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway.
    Biochem Biophys Res Commun, 326(2): 282-9. [Abstract] [Full-text]
34. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Steroids, 69(13): 795-801. [Abstract] [Full-text]
35. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
    Gynecol Oncol, 95(3): 456-62. [Abstract] [Full-text]
36. Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
    Life Sci, 76(7): 827-34. [Abstract] [Full-text]
37. Production of matrix metalloproteinases in specific subpopulations of human-patient breast cancer invading in three dimensional culture system.
    Life Sci, 76(7): 743-52. [Abstract] [Full-text]
38. Genomic instability in histologically normal breast tissues: implications for carcinogenesis.
    Lancet Oncol, 5(12): 753-8. [Abstract] [Full-text]
39. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Int J Cancer, 113(4): 575-80. [Abstract] [Full-text]
40. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Int J Cancer, 113(4): 678-82. [Abstract] [Full-text]
41. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
    Int J Cancer, 113(4): 654-9. [Abstract] [Full-text]
42. Magnetic resonance imaging of the breast prior to biopsy.
    JAMA, 292(22): 2735-42. [Abstract] [Full-text]
43. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Clin Cancer Res, 10(23): 8094-104. [Abstract] [Full-text]
44. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
    Clin Cancer Res, 10(23): 8068-76. [Abstract] [Full-text]
45. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    Clin Cancer Res, 10(23): 8059-67. [Abstract] [Full-text]
46. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
    Clin Cancer Res, 10(23): 7972-7. [Abstract] [Full-text]
47. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
    Clin Cancer Res, 10(23): 7965-71. [Abstract] [Full-text]
48. Long-term implications of bone loss in breast cancer.
    Breast, 13: S29-37. [Abstract] [Full-text]
49. The role of bisphosphonates in breast cancer.
    Breast, 13: S19-28. [Abstract] [Full-text]
50. Are all aromatase inhibitors the same? A review of the current evidence.
    Breast, 13: S10-8. [Abstract] [Full-text]
51. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
    Breast, 13: S3-9. [Abstract] [Full-text]
52. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.
    Proc Natl Acad Sci U S A, 101(49): 17210-5. [Abstract] [Full-text]
53. Providing psychosocial support for breast cancer patients based on screening for distress within a consultation-liaison service.
    Psychooncology, 13(12): 893-7. [Abstract] [Full-text]
54. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
    Am J Obstet Gynecol, 191(6): 1921-7. [Abstract] [Full-text]
55. Induction of apoptosis in MCF-7 human breast cancer cells by phytochemicals from Anoectochilus formosanus.
    J Biomed Sci, 11(6): 928-39. [Abstract] [Full-text]
56. Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma.
    J Biomed Sci, 11(6): 911-9. [Abstract] [Full-text]
57. TransMiner: mining transitive associations among biological objects from text.
    J Biomed Sci, 11(6): 864-73. [Abstract] [Full-text]
58. Trofosfamide in the palliative treatment of cancer: a review of the literature.
    Onkologie, 27(6): 572-6. [Abstract] [Full-text]
59. Breast cancer development in a female with Poland's syndrome.
    Onkologie, 27(6): 569-71. [Abstract] [Full-text]
60. Acute interstitial pneumopathy associated with docetaxel hypersensitivity.
    Onkologie, 27(6): 563-5. [Abstract] [Full-text]
61. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.
    J Mol Endocrinol, 33(3): 773-82. [Abstract] [Full-text]
62. Biologic comparison of partial breast irradiation protocols.
    Int J Radiat Oncol Biol Phys, 60(5): 1393-404. [Abstract] [Full-text]
63. Partial breast irradiation as second conservative treatment for local breast cancer recurrence.
    Int J Radiat Oncol Biol Phys, 60(5): 1385-92. [Abstract] [Full-text]
64. Localization of internal mammary lymph nodes by CT simulation: implications for breast radiation therapy planning.
    Radiother Oncol, 73(3): 355-7. [Abstract] [Full-text]
65. A case of neurofibromatosis and breast cancer: loss of heterozygosity of NF1 in breast cancer.
    Cancer Genet Cytogenet, 156(1): 86-8. [Abstract] [Full-text]
66. Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements.
    Cancer Genet Cytogenet, 156(1): 37-48. [Abstract] [Full-text]
67. Gene expression profile of an adenomyoepithelioma of the breast with a reciprocal translocation involving chromosomes 8 and 16.
    Cancer Genet Cytogenet, 156(1): 14-22. [Abstract] [Full-text]
68. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
    Biochem Pharmacol, 69(1): 123-32. [Abstract] [Full-text]
69. Synthesis and biological activities of bisnaphthalimido polyamines derivatives: cytotoxicity, DNA binding, DNA damage and drug localization in breast cancer MCF 7 cells.
    Biochem Pharmacol, 69(1): 19-27. [Abstract] [Full-text]
70. Biological inferences from a mathematical model of comedo ductal carcinoma in situ of the breast.
    J Theor Biol, 232(4): 523-43. [Abstract] [Full-text]
71. Insertional polymorphisms of endogenous HERV-K113 and HERV-K115 retroviruses in breast cancer patients and age-matched controls.
    AIDS Res Hum Retroviruses, 20(11): 1223-9. [Abstract] [Full-text]
72. Secretory carcinoma of the male breast: correlation of aspiration cytology and pathology.
    Diagn Cytopathol, 32(1): 47-50. [Abstract] [Full-text]
73. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
    Br J Pharmacol, 143(8): 933-7. [Abstract] [Full-text]
74. ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2.
    Oncogene, 23(57): 9295-302. [Abstract] [Full-text]
75. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?
    Cancer Immunol Immunother, 54(2): 149-56. [Abstract] [Full-text]
76. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
    Cancer Immunol Immunother, 54(2): 129-40. [Abstract] [Full-text]
77. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors.
    Cancer Lett, 217(1): 73-86. [Abstract] [Full-text]
78. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients.
    Cancer Lett, 217(1): 61-72. [Abstract] [Full-text]
79. Activation of GPR54 promotes cell cycle arrest and apoptosis of human tumor cells through a specific transcriptional program not shared by other Gq-coupled receptors.
    Biochem Biophys Res Commun, 326(3): 677-86. [Abstract] [Full-text]
80. 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474.
    J Proteome Res, 3(6): 1278-83. [Abstract] [Full-text]
81. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer.
    J Pathol, 205(1): 21-8. [Abstract] [Full-text]
82. Invasiveness of breast cancer cells MDA-MB-231 through extracellular matrix is increased by the estradiol metabolite 4-hydroxyestradiol.
    Int J Cancer, 113(5): 706-11. [Abstract] [Full-text]
83. Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units.
    Int J Cancer, 113(5): 857-9. [Abstract] [Full-text]
84. Tai Chi Chuan, health-related quality of life and self-esteem: a randomized trial with breast cancer survivors.
    Support Care Cancer, 12(12): 871-6. [Abstract] [Full-text]
85. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
    J Clin Invest, 114(12): 1714-25. [Abstract] [Full-text]
86. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
    Ann Oncol, 16(1): 70-4. [Abstract] [Full-text]
87. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Ann Oncol, 16(1): 64-9. [Abstract] [Full-text]
88. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
    Ann Oncol, 16(1): 56-63. [Abstract] [Full-text]
89. Do women read poster displays on breast cancer in waiting rooms?
    J Public Health (Oxf), 26(4): 355-8. [Abstract] [Full-text]
90. Phyllodes tumor of the seminal vesicle: case report and literature review.
    Pathol Int, 54(12): 924-9. [Abstract] [Full-text]
91. The interpersonal process model of intimacy: the role of self-disclosure, partner disclosure, and partner responsiveness in interactions between breast cancer patients and their partners.
    J Fam Psychol, 18(4): 589-99. [Abstract] [Full-text]
92. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Gynecol Oncol, 96(1): 222-6. [Abstract] [Full-text]
93. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.
    Br J Cancer, 91(12): 2012-7. [Abstract] [Full-text]
94. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases.
    Support Care Cancer, 12(12): 882-4. [Abstract] [Full-text]
95. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Support Care Cancer, 12(12): 877-81. [Abstract] [Full-text]
96. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.
    Support Care Cancer, 12(12): 852-8. [Abstract] [Full-text]
97. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.
    Support Care Cancer, 12(12): 844-51. [Abstract] [Full-text]
98. Association of a common variant of the CASP8 gene with reduced risk of breast cancer.
    J Natl Cancer Inst, 96(24): 1866-9. [Abstract] [Full-text]
99. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    J Natl Cancer Inst, 96(24): 1856-65. [Abstract] [Full-text]
100. Accuracy of screening mammography interpretation by characteristics of radiologists.
     J Natl Cancer Inst, 96(24): 1840-50. [Abstract] [Full-text]
101. Biennial versus annual mammography and the risk of late-stage breast cancer.
     J Natl Cancer Inst, 96(24): 1832-9. [Abstract] [Full-text]
102. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
     J Natl Cancer Inst, 96(24): 1823-31. [Abstract] [Full-text]
103. Work situation after breast cancer: results from a population-based study.
     J Natl Cancer Inst, 96(24): 1813-22. [Abstract] [Full-text]
104. Comparison of face-to-face and videoconferenced multidisciplinary clinical meetings.
     Australas Radiol, 48(4): 487-92. [Abstract] [Full-text]
105. Management of neuropathic pain following treatment for breast cancer in the absence of recurrence: a challenge for the radiation oncologist.
     Australas Radiol, 48(4): 459-65. [Abstract] [Full-text]
106. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
     Cancer, 102(6): 368-72. [Abstract] [Full-text]
107. Inconsistent self-reported mammography history: findings from the National Population Health Survey longitudinal cohort.
     BMC Health Serv Res, 4(1): 32. [Abstract] [Full-text]
108. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer.
     Oncogene, 23(58): 9432-7. [Abstract] [Full-text]
109. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
     Hum Reprod, 20(1): 294-301. [Abstract] [Full-text]
110. Implementation of DNA cytometric measurements in fine-needle aspiration biopsy diagnostics of breast disease.
     Cancer, 102(6): 380-8. [Abstract] [Full-text]
111. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
     Cancer Gene Ther, 12(1): 46-53. [Abstract] [Full-text]
112. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.
     Cancer Gene Ther, 12(1): 84-9. [Abstract] [Full-text]
113. Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice.
     Cancer Gene Ther, 12(1): 54-60. [Abstract] [Full-text]
114. Synchronous cancer and metastatic melanoma of the breasts.
     Arch Gynecol Obstet, 270(4): 290-1. [Abstract] [Full-text]
115. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes.
     Cancer Res, 64(24): 8987-93. [Abstract] [Full-text]
116. A novel RARbeta isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells.
     Cancer Res, 64(24): 8911-8. [Abstract] [Full-text]
117. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus.
     Cancer Res, 64(24): 8906-10. [Abstract] [Full-text]
118. Estrogen receptor genotypes and haplotypes associated with breast cancer risk.
     Cancer Res, 64(24): 8891-900. [Abstract] [Full-text]
119. Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.
     Breast Cancer Res Treat, 88(3): 287-8. [Abstract] [Full-text]
120. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality.
     Breast Cancer Res Treat, 88(3): 281-5. [Abstract] [Full-text]
121. Central nervous system metastases in women after multimodality therapy for high risk breast cancer.
     Breast Cancer Res Treat, 88(3): 273-80. [Abstract] [Full-text]
122. Possible role of Stat5a in rat mammary gland carcinogenesis.
     Breast Cancer Res Treat, 88(3): 263-72. [Abstract] [Full-text]
123. Bone mineral density and adjuvant therapy in breast cancer survivors.
     Breast Cancer Res Treat, 88(3): 257-61. [Abstract] [Full-text]
124. Increased frequency of long androgen receptor CAG repeats in male breast cancers.
     Breast Cancer Res Treat, 88(3): 239-46. [Abstract] [Full-text]
125. Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany.
     Breast Cancer Res Treat, 88(3): 231-7. [Abstract] [Full-text]
126. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer.
     Breast Cancer Res Treat, 88(3): 217-30. [Abstract] [Full-text]
127. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
     Breast Cancer Res Treat, 88(3): 209-15. [Abstract] [Full-text]
128. The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake.
     Breast Cancer Res Treat, 88(3): 205-8. [Abstract] [Full-text]
129. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype.
     Breast Cancer Res Treat, 88(3): 197-204. [Abstract] [Full-text]
130. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
     Crit Rev Oncol Hematol, 53(1): 81-9. [Abstract] [Full-text]
131. Naringenin-type flavonoids show different estrogenic effects in mammalian and teleost test systems.
     Biochem Biophys Res Commun, 326(4): 909-16. [Abstract] [Full-text]
132. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
     Med Hypotheses, 64(2): 337-41. [Abstract] [Full-text]
133. Lysosomal enzymes and initiation of breast cancer.
     Med Hypotheses, 64(2): 288-9. [Abstract] [Full-text]
134. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
     Med Hypotheses, 64(2): 248-51. [Abstract] [Full-text]
135. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1.
     Mol Cell Endocrinol, 229(1): 161-73. [Abstract] [Full-text]
136. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element.
     Mol Cell Endocrinol, 229(1): 127-39. [Abstract] [Full-text]
137. Novel 99mTc radiolabeled quinazolinone derivative [Qn-In]: synthesis, evaluation and biodistribution studies in mice and rabbit.
     Nucl Med Biol, 31(8): 1087-95. [Abstract] [Full-text]
138. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients.
     Clin Biochem, 38(1): 24-30. [Abstract] [Full-text]
139. Relationship between lesion size and signal enhancement on subtraction fat-suppressed MR imaging of the breast.
     Magn Reson Imaging, 22(9): 1259-64. [Abstract] [Full-text]
140. Non-resonant multiphoton photoacoustic spectroscopy for noninvasive subsurface chemical diagnostics.
     Appl Spectrosc, 58(11): 1325-33. [Abstract] [Full-text]
141. Fine needle aspiration cytology of mammary carcinoma with osteoclast-like giant cells.
     Cytopathology, 15(6): 321-5. [Abstract] [Full-text]
142. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
     Cytopathology, 15(6): 315-20. [Abstract] [Full-text]
143. Assessing HER-2 status in fresh frozen and archival cytological samples obtained by fine needle aspiration cytology.
     Cytopathology, 15(6): 311-4. [Abstract] [Full-text]
144. Interpretation of fine needle aspiration cytology of the breast: a comparison of cytological, frozen section, and final histological diagnoses.
     Cytopathology, 15(6): 297-304. [Abstract] [Full-text]
145. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
     Chem Res Toxicol, 17(12): 1577-83. [Abstract] [Full-text]
146. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
     J Clin Oncol, 22(24): 4958-65. [Abstract] [Full-text]
147. Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues.
     J Med Virol, 75(2): 276-81. [Abstract] [Full-text]
148. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
     J Clin Oncol, 22(24): 4951-7. [Abstract] [Full-text]
149. Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter.
     J Lab Clin Med, 144(6): 302-6. [Abstract] [Full-text]
150. United we stand? The effects of a couple-coping intervention on adjustment to early stage breast or gynecological cancer.
     J Consult Clin Psychol, 72(6): 1122-35. [Abstract] [Full-text]
151. 15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism.
     Carcinogenesis, 26(1): 81-92. [Abstract] [Full-text]
152. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
     Carcinogenesis, 26(1): 145-52. [Abstract] [Full-text]
153. Evaluation of serum KL-6 as a predictive marker of radiation pneumonitis in patients with breast-conservation therapy.
     Int J Clin Oncol, 9(6): 498-502. [Abstract] [Full-text]
154. Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2.
     Anesth Analg, 100(1): 244-9. [Abstract] [Full-text]
155. Comparative analysis of breast cancer risk factors among African-American women and White women.
     Am J Epidemiol, 161(1): 40-51. [Abstract] [Full-text]
156. Sentinel node biopsy in elderly breast cancer patients.
     Surg Oncol, 13(4): 193-6. [Abstract] [Full-text]
157. Age-related variations in progression of cancer at diagnosis and completeness of cancer registry data.
     Surg Oncol, 13(4): 175-9. [Abstract] [Full-text]
158. Origins and evolution of cell phenotypes in breast tumors.
     J Theor Biol, 233(1): 43-54. [Abstract] [Full-text]
159. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
     J Med Chem, 47(27): 6716-29. [Abstract] [Full-text]
160. Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage.
     BMC Cancer, 4(1): 78. [Abstract] [Full-text]
161. Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells.
     J Toxicol Environ Health A, 67(23): 2025-35. [Abstract] [Full-text]
162. 2-Hydroxyestradiol induces oxidative DNA damage and apoptosis in human mammary epithelial cells.
     J Toxicol Environ Health A, 67(23): 1939-53. [Abstract] [Full-text]
163. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2.
     J Biol Chem, 279(53): 55419-24. [Abstract] [Full-text]
164. Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix.
     Cell Mol Life Sci, 62(1): 65-76. [Abstract] [Full-text]
165. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
     Eur J Cancer, 41(1): 71-80. [Abstract] [Full-text]
166. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
     Cancer Lett, 217(2): 237-42. [Abstract] [Full-text]
167. Short-term effects of breast cancer on labor market attachment: results from a longitudinal study.
     J Health Econ, 24(1): 137-60. [Abstract] [Full-text]
168. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines.
     BMC Cancer, 4(1): 93. [Abstract] [Full-text]
169. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
     Cancer Chemother Pharmacol, 55(3): 286-94. [Abstract] [Full-text]
170. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
     Cancer Chemother Pharmacol, 55(3): 277-85. [Abstract] [Full-text]
171. Cryotherapy for breast fibroadenomas.
     Radiology, 234(1): 63-72. [Abstract] [Full-text]
172. Steroid receptor status, proliferation and metallothionein expression in primary invasive ductal breast cancers.
     Pathol Oncol Res, 10(4): 207-11. [Abstract] [Full-text]
173. Injection of (99m)Tc-labeled sulfur colloid the day before operation for breast cancer sentinel lymph node mapping is as successful as injection the day of operation.
     Am J Surg, 188(6): 685-9. [Abstract] [Full-text]
174. Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study.
     J Magn Reson Imaging, 21(1): 23-8. [Abstract] [Full-text]
175. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma.
     Cancer, 103(1): 164-73. [Abstract] [Full-text]
176. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma.
     Cancer, 103(1): 52-8. [Abstract] [Full-text]
177. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
     Cancer, 103(1): 44-51. [Abstract] [Full-text]
178. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
     Int J Cancer, 113(6): 911-9. [Abstract] [Full-text]
179. Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.
     Cell Biochem Funct, 23(1): 73-6. [Abstract] [Full-text]
180. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
     Surg Today, 35(1): 19-21. [Abstract] [Full-text]
181. Primary non-Hodgkin's lymphoma arising in an intramammary lymph node.
     Leuk Lymphoma, 46(3): 451-5. [Abstract] [Full-text]
182. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells.
     FEBS Lett, 579(1): 145-52. [Abstract] [Full-text]
183. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
     Clin Cancer Res, 10(24): 8720-7. [Abstract] [Full-text]
184. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
     Clin Cancer Res, 10(24): 8332-40. [Abstract] [Full-text]
185. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin.
     Clin Cancer Res, 10(24): 8275-83. [Abstract] [Full-text]
186. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
     Clin Cancer Res, 10(24): 8185-94. [Abstract] [Full-text]
187. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
     Clin Cancer Res, 10(24): 8163-9. [Abstract] [Full-text]
188. Circulating tumor cells in patients with breast cancer dormancy.
     Clin Cancer Res, 10(24): 8152-62. [Abstract] [Full-text]
189. Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman.
     J Clin Pathol, 58(1): 87-9. [Abstract] [Full-text]
190. Expression of prostate specific antigen in male breast cancer.
     J Clin Pathol, 58(1): 69-71. [Abstract] [Full-text]
191. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis.
     Proc Natl Acad Sci U S A, 101(52): 18147-52. [Abstract] [Full-text]
192. Malignant breast tumors after radiotherapy for a first cancer during childhood.
     J Clin Oncol, 23(1): 197-204. [Abstract] [Full-text]
193. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
     J Clin Oncol, 23(1): 41-8. [Abstract] [Full-text]
194. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
     N Engl J Med, 351(27): 2817-26. [Abstract] [Full-text]
195. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
     J Clin Oncol, 23(1): 24-9. [Abstract] [Full-text]
196. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.
     J Clin Oncol, 23(1): 17-23. [Abstract] [Full-text]
197. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment.
     J Clin Oncol, 23(1): 11-6. [Abstract] [Full-text]
198. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
     J Clin Oncol, 23(1): 30-40. [Abstract] [Full-text]
199. Gambling with your life: the process of breast cancer treatment decision making in Chinese women.
     Psychooncology, 14(1): 1-15. [Abstract] [Full-text]
200. Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutations.
     Psychooncology, 14(1): 34-48. [Abstract] [Full-text]
201. Existential plight of adult daughters following their mother's breast cancer diagnosis.
     Psychooncology, 14(1): 49-60. [Abstract] [Full-text]
202. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer.
     Psychooncology, 14(1): 70-8. [Abstract] [Full-text]
203. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
     J Biol Chem, 280(1): 54-63. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.